North-South Distribution of Solar Flares during Cycle 23

In this paper, we investigate the spatial distribution of solar flares in the northern and southern hemisphere of the Sun that occurred during the period 1996 to 2003. This period of investigation includes the ascending phase, the maximum and part of descending phase of solar cycle 23. It is revealed that the flare activity during this cycle is low compared to previous solar cycle, indicating the violation of Gnevyshev-Ohl rule. The distribution of flares with respect to heliographic latitudes shows a significant asymmetry between northern and southern hemisphere which is maximum during the minimum phase of the solar cycle. The present study indicates that the activity dominates the northern hemisphere in general during the rising phase of the cycle (1997-2000). The dominance of northern hemisphere is shifted towards the southern hemisphere after the solar maximum in 2000 and remained there in the successive years. Although the annual variations in the asymmetry time series during cycle 23 are quite different from cycle 22, they are comparable to cycle 21.Comment: 6 pages, 2 figures, 1 table; Accepted for the publication in the proceedings of international solar workshop held at ARIES, Nainital, India on "Transient Phenomena on the Sun and Interplanetary Medium" in a special issue of "Journal of Astrophysics and Astronomy (JAA)

Dermatomyositis complicating penicillamine treatment.

SUMMARY A case of dermatomyositis developing during the course of treatment with D-penicil-lamine in a patient with rheumatoid arthritis is described. Complete remission occurred on with-drawal of the drug. Possible alternative diagnoses are discussed. Penicillamine, which has been used successfully for many years in the long-term treatment of Wilson's disease and cystinuria, is now being used increasingly in the treatment of rheumatoid arthritis. Unfortu-nately, side effects are frequent and often lead to discontinuance of the drug. They include nausea and vomiting, rashes, loss of taste, thrombocytopenia, and immune-complex nephritis. Less common side effects are drug-induced systemic lupus erythemato-sus (Day and Golding, 1974) and myasthenia gravis (Bucknall et al., 1975). There have also been three single case reports of polymyositis occurring durin

Predicting the Amplitude of a Solar Cycle Using the North-South Asymmetry in the Previous Cycle: II. An Improved Prediction for Solar Cycle~24

Recently, using Greenwich and Solar Optical Observing Network sunspot group data during the period 1874-2006, (Javaraiah, MNRAS, 377, L34, 2007: Paper I), has found that: (1) the sum of the areas of the sunspot groups in 0-10 deg latitude interval of the Sun's northern hemisphere and in the time-interval of -1.35 year to +2.15 year from the time of the preceding minimum of a solar cycle n correlates well (corr. coeff. r=0.947) with the amplitude (maximum of the smoothed monthly sunspot number) of the next cycle n+1. (2) The sum of the areas of the spot groups in 0-10 deg latitude interval of the southern hemisphere and in the time-interval of 1.0 year to 1.75 year just after the time of the maximum of the cycle n correlates very well (r=0.966) with the amplitude of cycle n+1. Using these relations, (1) and (2), the values 112 + or - 13 and 74 + or -10, respectively, were predicted in Paper I for the amplitude of the upcoming cycle 24. Here we found that in case of (1), the north-south asymmetry in the area sum of a cycle n also has a relationship, say (3), with the amplitude of cycle n+1, which is similar to (1) but more statistically significant (r=0.968) like (2). By using (3) it is possible to predict the amplitude of a cycle with a better accuracy by about 13 years in advance, and we get 103 + or -10 for the amplitude of the upcoming cycle 24. However, we found a similar but a more statistically significant (r=0.983) relationship, say (4), by using the sum of the area sum used in (2) and the north-south difference used in (3). By using (4) it is possible to predict the amplitude of a cycle by about 9 years in advance with a high accuracy and we get 87 + or - 7 for the amplitude of cycle 24.Comment: 21 pages, 7 figures, Published in Solar Physics 252, 419-439 (2008

Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells

Epidermal growth factor receptor (EGFR) is an important regulator of epithelial cell growth and survival in normal and cancerous tissues and is a principal therapeutic target for cancer treatment. EGFR is associated in epithelial cells with the heavily glycosylated transmembrane mucin protein MUC1, a natural ligand of galectin-3 that is overexpressed in cancer. This study reveals that the expression of cell surface MUC1 is a critical enhancer of EGF-induced EGFR activation in human breast and colon cancer cells. Both the MUC1 extracellular and intracellular domains are involved in EGFR activation but the predominant influence comes from its extracellular domain. Binding of galectin-3 to the MUC1 extracellular domain induces MUC1 cell surface polarization and increases MUC1–EGFR association. This leads to a rapid increase of EGFR homo-/hetero-dimerization and subsequently increased, and also prolonged, EGFR activation and signalling. This effect requires both the galectin-3 C-terminal carbohydrate recognition domain and its N-terminal ligand multi-merization domain. Thus, interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in epithelial cancer cells. As MUC1 and galectin-3 are both commonly overexpressed in most types of epithelial cancers, their interaction and impact on EGFR activation likely makes important contribution to EGFR-associated tumorigenesis and cancer progression and may also influence the effectiveness of EGFR-targeted cancer therapy

Design of the beam delivery system for the International Linear Collider

online : http://pac07.org/proceedings/PAPERS/WEOCAB01.PDFInternational audienceThe beam delivery system for the linear collider focuses beams to nanometer sizes at its interaction point, collimates the beam halo to provide acceptable background in the detector and has a provision for state-of-the-art beam instrumentation in order to reach the ILCs physics goals. this paper describes the design details and status of the baseline configuration considered for the reference design and also lists alternatives

Is there an enhancement of muons at sea level from transient events?

In a recent study of a search for enhancements from the galactic center with muons at sea level using the TUPI muon telescope, we have found several ground level enhancements (GLEs) as very sharp peaks above the count rate background. This paper reports a consistent analysis of two GLEs observed in December 2003 and detected after an up-grade of the data acquisition system, which includes a noise filter and which allows us to verify that the GLEs are not mere background fluctuations. The main target of this study is a search for the origin of the GLEs. The results show that one of them has a strong correlation with a solar flare, while the other has an unknown origin, because there is neither a satellite report of a solar flare, nor prompt X-ray emission, and nor a excess of nuclei during the raster scan where the GLE was observed. Even so, two possibilities are analyzed: the solar flare hypothesis and the gamma ray burst (GRB) hypothesis. We show, by using the FLUKA Monte Carlo results for photo-production, that under certain conditions there is the possibility of an enhancement of muons at sea level from GeV GRBs.Comment: 27 pages, 11 ps figures, Accepted in Astrophysical Journa

ATF2 COMMISSIONING

ATF2 is a final-focus test beam line that aims to focus the low-emittance beam from the ATF damping ring to a beam size of about 37 nm, and at the same time to demonstrate nm beam stability, using numerous advanced beam diagnostics and feedback tools. The construction has been finished at the end of 2008 and the beam commissioning of ATF2 has started in December of 2008. ATF2 is constructed and commissioned by ATF international collaborations with strong US, Asian and European participation

How Do Young Adults Prefer to Access Mental Health Information?

KT strategies for sharing mental health information need to include both active and passive options for young adults. This includes the use of both old and new media tools.York’s Knowledge Mobilization Unit provides services and funding for faculty, graduate students, and community organizations seeking to maximize the impact of academic research and expertise on public policy, social programming, and professional practice. It is supported by SSHRC and CIHR grants, and by the Office of the Vice-President Research & Innovation. [email protected] www.researchimpact.c

An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma

Background: An improved understanding of which gastroesophageal adenocarcinoma (GOA) patients respond to both chemotherapy and immune checkpoint inhibitors (ICI) is needed. We investigated the predictive role and underlying biology of a 44-gene DNA damage immune response (DDIR) signature in patients with advanced GOA.Materials and methods: Transcriptional profiling was carried out on pretreatment tissue from 252 GOA patients treated with platinum-based chemotherapy (three dose levels) within the randomized phase III GO2 trial. Cross-validation was carried out in two independent GOA cohorts with transcriptional profiling, immune cell immunohistochemistry and epidermal growth factor receptor (EGFR) fluorescent in situ hybridization (FISH) (n = 430).Results: In the GO2 trial, DDIR-positive tumours had a greater radiological response (51.7% versus 28.5%, P = 0.022) and improved overall survival in a dose-dependent manner (P = 0.028). DDIR positivity was associated with a pretreatment inflamed tumour microenvironment (TME) and increased expression of biomarkers associated with ICI response such as CD274 (programmed death-ligand 1, PD-L1) and a microsatellite instability RNA signature. Consensus pathway analysis identified EGFR as a potential key determinant of the DDIR signature. EGFR amplification was associated with DDIR negativity and an immune cold TME.Conclusions: Our results indicate the importance of the GOA TME in chemotherapy response, its relationship to DNA damage repair and EGFR as a targetable driver of an immune cold TME. Chemotherapy-sensitive inflamed GOAs could benefit from ICI delivered in combination with standard chemotherapy. Combining EGFR inhibitors and ICIs warrants further investigation in patients with EGFR-amplified tumours

Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial

Introduction Research into the optimal management of frail patients with cancer is limited and treatment decision-making in this cohort can be difficult. A number of measures have been developed to assess frailty, but few studies explore the correlation between frailty measures and cancer treatment outcomes. Methods This retrospective cohort study is an exploratory analysis of the GO2 randomised controlled trial. GO2 recruited both older and frail younger patients commencing first-line palliative chemotherapy for advanced gastro-oesophageal (aGO) cancer. This analysis aims to explore the correlation between baseline frailty and treatment outcome. Baseline frailty measures were derived from clinical data and included ECOG Performance Status (PS), the GO2 Frailty Score (GO2FS), Geriatric-8 (G8), Cancer and Aging Research Group (CARG) toxicity score and a ‘modified’ Rockwood Clinical Frailty Scale (mCFS). Novel patient-centred composite measure Overall Treatment Utility (OTU) was the primary endpoint. Ordinal logistic regression was undertaken to give odds ratios for poor vs good/intermediate OTU. Secondary endpoints were progression-free and overall survival. Models were adjusted for age, sex, histology, metastases, Trastuzumab and renal/hepatic function. Results In GO2, 514 patients were randomised between three chemotherapy dose-levels; all of these patients were assessed for OTU and are included in this analysis. Worse GO2FS, mCFS and G8 scores all had a statistically significant association with poor (vs good/intermediate) OTU, progression and death, which persisted after adjustment. Adjusted odds ratios for poor OTU amongst those with the worst GO2FS and mCFS and best G8 scores were as follows: 1.85 (95% confidence interval [CI] 1.20–2.88) for GO2FS ≥3 (‘severely frail’), 1.72 (1.19–2.50) for mCFS 5+ (‘frail’) and 0.57 (0.32–1.00) for G8 > 14 (‘normal’). Worse ECOG PS and CARG scores did not have a statistically significant association with poor OTU/progression/death. Conclusion In this study, frailty identified via GO2FS, mCFS and G8 conveyed a statistically significant increased risk of worse treatment outcome in older and frail younger patients with aGO cancer. Frailty assessment provides information over and above PS and should be integrated alongside routine assessments in research and clinical practice. In the absence of prospective data, frailty measures can be derived retrospectively to build the evidence base around optimal care of frailer patients